fls.txt



item1.txt
2016-02, Leases, which replaces previous lease guidance in its entirety with ASC 842 and requires lessees to recognize lease assets and lease liabilities for those arrangements classified as operating leases under previous guidance, with the exception of leases with a term of twelve months or less.
The following table summarizes the Company’s disaggregation of revenues for the three months ended September 30, 2019 and 2018.
Normally, the Company warrantees its instruments for a period of twelve months for parts and labor which normally consists of replacement of small components or software support.
Approximately 36% and 49% of net sales of Benchtop Laboratory Equipment for the three month periods ended September 30, 2019 and 2018, respectively, were derived from the Company’s main product, the Vortex-Genie 2 mixer, excluding accessories.
Approximately 33% and 25% of total Benchtop Laboratory Equipment sales were derived from the Torbal Scales Division for the three months ended September 30, 2019 and 2018, respectively.
For the three months ended September 30, 2019 and 2018, respectively, three customers accounted for approximately 23% (both periods) of net sales of the Benchtop Laboratory Equipment Operations (18% and 19% of the Company’s total revenues).
Sales to two customers during the three months ended September 30, 2019 accounted for approximately 90% of the Catalyst Research Instruments Operations revenues and 6% of the Company’s total revenues.
Sales to three customers during the three months ended September 30, 2018 accounted for approximately 83% of the Catalyst Research Instrument Operations’ revenues and 9% of the Company’s total revenues.
The FASB defines the fair value of financial instruments as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.
The Company calculated the fair value of its Level 1 and 2 instruments based on the exchange traded price of similar or identical instruments where available or based on other observable instruments.
The Company has not changed its valuation techniques in measuring the fair value of any financial assets and liabilities during the period.
The measurement is based on significant inputs that are not observable in the market, therefore, the Company classifies this liability as Level 3 in the following tables.
Goodwill represents the excess of the purchase price over the fair value of the net assets acquired in connection with the Company’s acquisitions.
On July 1, 2019 the Company adopted the new accounting pronouncement as it relates to its leases which requires a lessee to recognize all long-term leases on its balance sheet as a liability for its lease obligation, measured at the present value of lease payments not yet paid, and a corresponding asset representing its right to use the underlying asset over the lease term and expands disclosure of key information about leasing arrangements.
The Company leases certain properties consisting principally of a facility in Bohemia, New York (headquarters) through February 2025, a facility in Pittsburgh, Pennsylvania for its Catalyst Research Instrument Operations through November 2020 and another facility in Pittsburgh, Pennsylvania for its Bioprocessing Systems Operations through November 2020.
In addition, the Company had a lease for its Torbal Division of the Benchtop Laboratory Equipment Operations which was mutually terminated early effective as of October 31, 2019 and a new lease for a similar sales and administration office was entered into as of November 1, 2019 through October 2022.
All of the Company’s leases are deemed operating leases.


item2.txt
The Company reflected a loss before income tax expense of $75,700 for the three months ended September 30, 2019 compared to income before tax expense of $177,500 for the three months ended September 30, 2018, primarily from the result of decreased revenues and gross margins for the Benchtop Laboratory Equipment Operations resulting from reduced orders from Asia, primarily China, and increased component costs as a result of tariffs imposed.
The results reflected total non-cash amounts for depreciation and amortization of $41,000 and $75,900 for the three months ended September 30, 2019 and 2018, respectively.
Net revenues for the three months ended September 30, 2019 decreased $34,400 (1.7%) to $2,004,200 from $2,038,600 for the three months ended September 30, 2018, reflecting a decrease of $115,700 (6.8%) decrease in net sales of Benchtop Laboratory Equipment primarily due to sales of its Genie brand products to Asia, particularly China.
The Benchtop Laboratory Equipment sales reflected $522,400 of Torbal brand product sales for the three months ended September 30, 2019, compared to $425,300 in the three months ended September 30, 2018 as a result of continued growth in sales of the new force gauges product line.
Sales of Catalyst Research Instruments decreased by $78,800 to $138,700 for the three months ended September 30, 2019 compared to $217,500 for the three months ended September 30, 2018 due to low order input during the period.
Revenues derived from the Bioprocessing Systems Operations which are comprised primarily of net royalties accrued from sublicenses increased by $160,100 (123.9%) to $289,300 for the three months ended September 30, 2019 compared to $129,200 for the three months ended September 30, 2018 due to increased royalties on Europe sales.
General and administrative expenses for the three months ended September 30, 2019 increased by $93,700 (22.5%) to $510,200 compared to $416,500 for the three months ended September 30, 2018 mainly due to the ramp up in Scientific Bioprocessing Operations, and various other corporate expenses.
Selling expenses for the three months ended September 30, 2019 increased $73,000 (30.9%) to $309,100 from $236,100 for the three months ended September 30, 2018 primarily due to increased market research and marketing activities by the Bioprocessing Systems Operations, and to a lesser extent increased marketing by the Benchtop Laboratory Equipment Operations.
Research and development expenses increased by $119,200 (101.5%) to $236,600 for the three months ended September 30, 2019 compared to $117,400 for the three months ended September 30, 2018, mainly due to the ramp up in product development activities by the Bioprocessing Systems Operations which included staffing and materials.


